在轴性脊椎关节炎中个性化非类固醇抗炎药物治疗:使用贝叶斯分析的N-of-1试验
Mark C Hwang1, Seokhun Kim2, Shervin Assassi1,2
1Division of Rheumatology, Department of Internal Medicine, John P. and Kathrine G. McGovern School of Medicine at The University of Texas Health Science Center at Houston, Houston, TX, USA.
Rheumatology (Oxford, England)
|July 17, 2025
概括
使用贝叶斯的N-of-1试验对轴性脊柱关节炎 (axSpA) 进行个性化非类固醇抗炎药物 (NSAID) 治疗,优化了治疗. 这种个性化的方法提高了治疗axSpA症状的有效性和患者偏好.
科学领域:
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 轴性脊椎关节炎 (axSpA) 是一种慢性炎症疾病,影响脊椎和关节.
- 非类固醇抗炎药物 (NSAIDs) 是主要的治疗方法,但患者的反应有很大差异.
研究的目的:
- 评估 axSpA.中的三种NSAIDs (celecoxib, meloxicam, naproxen) 的疗效和患者偏好.
- 通过使用贝叶斯 N-of-1 试验进行个性化的 NSAID 选择来优化 axSpA 管理.
主要方法:
- 对42名axSpA患者进行了随机双盲交叉N-of-1试验.
- 利用贝叶斯分析来评估个体患者对NSAIDs在两个4周周期中的反应.
- 通过结性脊柱炎疾病活动评分 (ASDAS) 的变化来衡量治疗的有效性.
主要成果:
- 所有测试的NSAID都降低了患者的ASDAS分数,表明了整体疗效.
- 没有单一的NSAID对所有人来说都优越;患者的偏好和反应高度个性化.
- 与最不喜欢的NSAID相比,每个患者最喜欢的NSAID显示出明显更大的ASDAS减少.
结论:
- 贝叶斯的N-of-1试验有效地个性化了对axSpA的NSAID治疗,优化了疗效和耐受性.
- 与标准护理相比,这种个性化的治疗策略为管理axSpA提供了更有效的方法.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
177
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
177
01:29Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
236
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
236
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
127
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
127